The past form of medicine, limited by the level of science and technology at that time, only aimed at removing and alleviating the patient’s pain, but modern medicine has added a lot of health care medicine and preventive medicine to the original structure of clinical medicine, which means taking into account elements such as improving the quality of life and reducing risk factors. Therefore, from the perspective of modern medicine, all hepatitis B virus carriers are classified as unhealthy people with health risks, and those who are HBV-DNA positive carriers also have infectious risks, so they are entitled to medical attention. However, due to the constraints of patients’ awareness of the dangers of virus carriage, economic conditions and available treatment, most carriers have to adopt an attitude of patience and waiting, and suffer the health risks and psychological crises in silence. What we can do is to explore more effective treatment methods under the existing conditions, or significantly reduce the cost of treatment without significantly lowering the efficacy, so that as many hepatitis B carriers as possible can eventually benefit from the health of hepatitis B carriers. The health benefits of treatment. The desire of the hepatitis B carrier community itself for access to treatment is universal. The reason for this is firstly, that deaths caused by cirrhosis and liver cancer caused by hepatitis B virus infection are concentrated in the age group of 40-55 years old, and that carriers of hepatitis B virus have a high concentration of family members, so when carriers of hepatitis B virus witness the death of more than one member of the family at almost the same age, the horror of the countdown to life looms large. The third is the fear of spreading the virus they carry to their families, especially to their offspring. These restrictions cannot be eliminated in the short term, either by legal means or through scientific education. As one of my young patients said: “I am so tired, in this society of competition on the basis of strength, I am not inferior to others in terms of ability, knowledge, or physical appearance, but because I have this problem, I have to lose one opportunity after another, and I don’t know what kind of frustration is waiting for me tomorrow”. In some cases it can be said that “the psychological damage of a hepatitis B carrier exceeds its pathological damage, and the damage caused by external stress exceeds the damage that exists in itself”. It has been proven that it is feasible to give priority to antiviral trial treatment for those who want to be treated even though they know that the efficacy rate is not high, as long as it is explained in advance. On the contrary, if formal medical institutions adopt a “one-size-fits-all” approach to keep all carriers out of antiviral treatment, they will neglect the proper guidance and management of this group and increase the negative consequences of this group entering the informal medical field. Although hepatitis B carriers are far less critical than clinical chronic hepatitis, their immune deficiencies are more severe. The immune-tolerant group facing treatment is a group with varying degrees of immune deficiency, and it is very difficult to escape from immune tolerance in a natural state, especially under the pressure of chronic high viral load replication. After antiviral treatment, the body is in a state of low viral replication for a long period of time, which creates favorable conditions for some mild immunodeficient people to break the immune tolerance. The purpose of antiviral treatment for hepatitis B carriers is to create opportunities for as many hepatitis B carriers as possible to enter the virus clearance period. Antiviral therapy for virus carriers is characterized by high investment, long course of treatment and low efficacy. The unsatisfactory performance in general is certain, but it is also certain to make some treated people achieve efficacy. In other words, although it does not seem realistic to achieve permanent DNA conversion in all treated patients, it is now possible to achieve DNA conversion or decline in all users over time, and it is now possible to achieve permanent DNA conversion in some treated patients. The only regret is that, with current testing technology, it is not possible to assess the degree of immunodeficiency in the population before treatment, so there is a large degree of blindness to whether immune tolerance can be broken after antiviral therapy for the treated population, and because the degree of immunodeficiency is not supported by testing, the only feedback on the efficacy of antiviral therapy is the efficacy of the treatment.